Center for Biomolecular Sciences, University of Illinois, Chicago, Illinois 60607, USA; email:
Annu Rev Microbiol. 2018 Sep 8;72:185-207. doi: 10.1146/annurev-micro-090817-062329. Epub 2018 Jun 15.
The ribosome is a major antibiotic target. Many types of inhibitors can stop cells from growing by binding at functional centers of the ribosome and interfering with its ability to synthesize proteins. These antibiotics were usually viewed as general protein synthesis inhibitors, which indiscriminately stop translation at every codon of every mRNA, preventing the ribosome from making any protein. However, at each step of the translation cycle, the ribosome interacts with multiple ligands (mRNAs, tRNA substrates, translation factors, etc.), and as a result, the properties of the translation complex vary from codon to codon and from gene to gene. Therefore, rather than being indiscriminate inhibitors, many ribosomal antibiotics impact protein synthesis in a context-specific manner. This review presents a snapshot of the growing body of evidence that some, and possibly most, ribosome-targeting antibiotics manifest site specificity of action, which is modulated by the nature of the nascent protein, the mRNA, or the tRNAs.
核糖体是一种主要的抗生素靶标。许多类型的抑制剂可以通过结合核糖体的功能中心并干扰其合成蛋白质的能力来阻止细胞生长。这些抗生素通常被视为通用的蛋白质合成抑制剂,它们不加区分地在每个 mRNA 的每个密码子处停止翻译,从而阻止核糖体合成任何蛋白质。然而,在翻译周期的每个步骤中,核糖体都与多种配体(mRNA、tRNA 底物、翻译因子等)相互作用,因此,翻译复合物的性质在密码子和基因之间都有所不同。因此,许多核糖体抗生素并不是不分青红皂白的抑制剂,而是以特定于上下文的方式影响蛋白质合成。这篇综述介绍了越来越多的证据,表明一些(可能是大多数)靶向核糖体的抗生素表现出作用的位点特异性,这种特异性受到新生蛋白质、mRNA 或 tRNA 的性质的调节。